Centre de Référence Maladies Rares


Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC)

FR: Biologie Fondamentale Appliquée à la Médecine

U1035Display navigation INSERM U1035 FR / EN

Christophe GROSSET

INSERM PhD, Research DirectorHead of MiRCaDe team,



Study the molecular processes, signaling pathways (Wnt, Fanconi Anemia, RAS/RAF/MEK/ERK) genes and microRNAs involved in liver carcinogenesis in adults (hepatocellular carcinoma) and children (hepatoblastoma).


1. Grosset, C, CY Chen, N Xu, N Sonenberg, H Jacquemin-Sablon, and AB Shyu, A mechanism for translationally coupled mRNA turnover: interaction between the poly(A) tail and a c-fos RNA coding determinant via a protein complex. Cell, 2000. 103(1): p. 29-40.
2. Solanilla, A, C Grosset, C Lemercier, M Dupouy, FX Mahon, K Schweitzer, J Reiffers, B Weksler, and J Ripoche, Expression of Flt3-ligand by the endothelial cell. Leukemia, 2000. 14(1): p. 153-62.
3. Harizi, H, M Juzan, C Grosset, M Rashedi, and N Gualde, Dendritic cells issued in vitro from bone marrow produce PGE that contributes to the immunomodulation induced by antigen-presenting cells. Cell Immunol, 2001. 209(1): p. 19-28.
4. Grosset, C, R Boniface, P Duchez, A Solanilla, B Cosson, and J Ripoche, In vivo studies of translational repression mediated by the granulocyte-macrophage colony-stimulating factor AU-rich element. J Biol Chem, 2004. 279(14): p. 13354-62.
5. Solanilla, A, JM Pasquet, JF Viallard, C Contin, C Grosset, J Dechanet-Merville, M Dupouy, M Landry, F Belloc, P Nurden, P Blanco, JF Moreau, JL Pellegrin, AT Nurden, and J Ripoche, Platelet-associated CD154 in immune thrombocytopenic purpura. Blood, 2005. 105(1): p. 215-8.
6. Sagliocco, F, B Laloo, B Cosson, L Laborde, M Castroviejo, J Rosenbaum, J Ripoche, and C Grosset, The ARE-associated factor AUF1 binds poly(A) in vitro in competition with PABP. Biochem J, 2006. 400(2): p. 337-47.
7. Laloo, B, D Simon, V Veillat, D Lauzel, V Guyonnet-Duperat, F Moreau-Gaudry, F Sagliocco, and C Grosset, Analysis of post-transcriptional regulations by a functional, integrated, and quantitative method. Mol Cell Proteomics, 2009. 8(8): p. 1777-88.
8. Simon, D, B Laloo, M Barillot, T Barnetche, C Blanchard, C Rooryck, M Marche, I Burgelin, I Coupry, N Chassaing, B Gilbert-Dussardier, D Lacombe, C Grosset, and B Arveiler, A mutation in the 3’-UTR of the HDAC6 gene abolishing the post-transcriptional regulation mediated by hsa-miR-433 is linked to a new form of dominant X-linked chondrodysplasia. Hum Mol Genet, 2010. 19(10): p. 2015-27.
9. Jalvy-Delvaille, S., M. Maurel, V. Majo, N. Pierre, S. Chabas, C. Combe, J. Rosenbaum, F. Sagliocco, and C.F. Grosset, Molecular basis of differential target regulation by miR-96 and miR-182: the Glypican-3 as a model. Nucleic Acids Res, 2012. 40(3): p. 1356-65.
10. Maurel, M., S. Jalvy, Y. Ladeiro, C. Combe, L. Vachet, F. Sagliocco, P. Bioulac-Sage, V. Pitard, H. Jacquemin-Sablon, J. Zucman-Rossi, B. Laloo, and C.F. Grosset, A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma. Hepatology, 2013. 57(1): p. 195-204.
11. Maurel, M., Dejeans, N., Taouji, S., Chevet, E. and C.F. Grosset. MicroRNA-1291-mediated silencing of IRE1alpha enhances Glypican-3 expression. RNA, 2013. 19, 778-788.
12. Indersie, E, S Lesjean, KB Hooks, F Sagliocco, T Ernault, S Cairo, M Merched-Sauvage, A Rullier, B Le Bail, S Taque, M Grotzer, S Branchereau, C Guettier, M Fabre, L Brugières, M Hagedorn, MA Buendia, and CF Grosset, MicroRNA therapy inhibits hepatoblastoma growth in vivo by targeting beta-catenin and Wnt signaling. Hepatol Comm, 2017. 1(2): p. 168-183.
13. Cartier F, Indersie E, Lesjean S, Charpentier J, Hooks KB, Ghousein A, Desplat A, Dugot-Senant N, Trezeguet V, Sagliocco F, Hagedorn M, Grosset CF. New tumor suppressor microRNAs target glypican-3 in human liver cancer. Oncotarget 2017;8(25):41211-26. doi: 10.18632/oncotarget.17162
14. Audoux, J, M Salson, CF Grosset, S Beaumeunier, JM Holder, T Commes, and N Philippe, SimBA: A methodology and tools for evaluating the performance of RNA-Seq bioinformatic pipelines. BMC Bioinformatics, 2017. 18(1): p. 428.
15. Hooks, KB, J Audoux, H Fazli, S Lesjean, T Ernault, N Dugot-Senant, T Leste-Lasserre, M Hagedorn, B Rousseau, C Danet, S Branchereau, L Brugières, S Taque, C Guettier, M Fabre, A Rullier, MA Buendia, T Commes, A Raymond*, and CF Grosset*, New insights into diagnosis and therapeutic options for proliferative hepatoblastoma. Hepatology, 2018 Jul;68(1):89-102. doi: 10.1002/hep.29672. co-last authors. *SIOP 2018 Poster Award.
16. Saad, A, B Liet, G Joucla, X Santarelli, J Charpentier, S Claverol, CF Grosset, and V Trézéguet, Role of O-glycanation and convertase maturation of the soluble Glypican-3 in inhibiting proliferation of hepatocellular carcinoma cells. Biochemistry, 2018 Feb 20;57(7):1201-1211. doi: 10.1021/acs.biochem.7b01208.
17. Indersie, E*, KB Hooks*, C Capdevielle, M Fabre, N Dugot-Senant, A Desplat, S Lepreux, A Merched, CF Grosset, and M Hagedorn, Tracking cellular and molecular changes in a species-specific manner during experimental hepatoblastoma progression in vivo. Oncotarget, 2018 Mar 1;9(22):16149-16162. doi: 10.18632/oncotarget.24598. * co-first authors.
18. A Ghousein, N Mosca, F Cartier, J Charpentier, J-W Dupuy, A-A Raymond, P Bioulac-Sage and CF Grosset. miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signaling inactivation. Liver International, 2019, 10.1111/liv.14276.
19. L Azzi-Martin, W He, C Péré-Védrenne, V Korolik, C Alix, M Prochazkova-Carlotti, JL Morel, E Le Roux-Goglin, P Lehours, M Djavaheri-Mergny, CF Grosset, C Varon, P Dubus, A Ménard. Cytolethal distending toxin induces the formation of transient messenger-rich ribonucleoprotein nuclear invaginations in surviving cells. Plos Pathogens. 2019 Sep 30;15(9):e1007921. doi: 10.1371/journal.ppat.1007921. eCollection 2019 Sep.
20. D Loncaric, B. Stankovic, A Ghousein, M. Vreca, V. Spasenovski, A. Villacreces, C. Debeissat, C. Grosset, Zoran Ivanovic, Sonja Pavlovic1. Expression of miR-210 in human bone marrow derived mesenchymal stromal cells under oxygen deprivation conditions. Archives in Biological Sciences 2019, Arch Biol Sci. 2019;71(2):201-208. doi.org/10.2298/ABS181117001L
21. Péré-Védrenne Christelle Wencan, He, Lamia Azzi-Martin, Valérie Prouzet-Mauléon, Alice Buissonnière, Bruno Cardinaud, Philippe Lehours, Francis Mégraud, Christophe F. Grosset and Armelle Ménard. The nuclear remodeling induced by the cytolethal distending toxin of Helicobacter involves MAFB oncoprotein. Toxins (Basel). 2020 Mar 12;12(3):174. doi: 10.3390/toxins12030174.
22. Capdevielle, C, A Desplat, J Charpentier, F Sagliocco, P Thiebaud, N Theze, S Fédou, KB Hooks, V Guyonnet-Duperat, M Pretel, AA Raymond, JW Dupuy, CF Grosset, and M Hagedorn, HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53. Neuro-Oncology, Volume 22, Issue 4, April 2020, Pages 550–562, https://doi.org/10.1093/neuonc/noz215


1. V Trézéguet and CF Grosset. MicroRNAs, small genic regulators with high therapeutic potential in oncology, Bull Cancer. Article in French. 2019 Sep 5. pii: S0007-4551(19)30264-4. doi: 10.1016/j.bulcan.2019.08.002.
2. V Trézéguet and CF Grosset. MicroRNAs, Small Gene Regulators with High Therapeutic Promise in Oncology. Gastro Med Res. 3(3). GMR.000565. 2019. doi: 10.31031/GMR.2019.03.000565.
3. V Trézéguet and CF Grosset. MicroRNAs and their therapeutic potential in oncology: an overview in 2019. Article in French. 2019, J Biol Med, 2020 Jan-Mar, 8(2): p271-277.

Other products

1. 3rd colloquium on fundamental research in paediatric oncology. Trézéguet V, Lesjean S, Veschambre P, Auguste P, Turcq B, Ducassou S, Merched A, Grosset CF. Bull Cancer. 2020 Dec;107(12):1284-1287. doi: 10.1016/j.bulcan.2020.07.012.


  • Use of Glypican-3-targeting microRNAs for treating liver cancer. n° B2058PC00; PCT/EP2016/065933 European patent UNIVERSITE DE BORDEAUX-INSERM
  • Use of catenin-beta 1-targeting microRNAs for treating liver cancer. n°B2059PC00; PCT/EP2016/065938 European patent UNIVERSITE DE BORDEAUX-INSERM-UNIVERSITE PARIS SUD - PARIS XI


Back to organigramme

INSERM U1035 - University of Bordeaux
146 rue Léo Saignat - PE building south zone, 4th floor
33000 Bordeaux
Work +33 557 57 13 73/74